He is specialized in haematology and haematopathology. His clinical work focuses on the management of haematological malignancies. His team has especial interests in the treatment of leukaemias and T-cell and natural killer cell malignancies. His research centres on the molecular pathogenetic pathways and novel treatment modalities in haematological neoplasms. Together with the clinical pharmacology team in his department, Professor Kwong has pioneered the development and use of oral arsenic trioxide in the treatment of acute promyelocytic leukaemia and other blood cancers. His research team is also actively involved in defining the molecular defects and optimal treatment protocols for T-cell and natural killer cell lymphomas, which are neoplasms prevalent in Asian populations.